首页> 外文期刊>Journal of chemotherapy >Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme.
【24h】

Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme.

机译:来自欧洲重症监护病房的革兰氏阴性菌株的抗菌素耐药性:来自美罗培南年度药敏试验信息收集(MYSTIC)计划的数据。

获取原文
获取原文并翻译 | 示例
           

摘要

Susceptibility data were collected for 6243 gram-negative isolates from 29 European ICUs participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme (1997-2000). The most commonly isolated bacteria were Pseudomonas aeruginosa (22.5%), Escherichia coli (19.8%), Klebsiella pneumoniae (10.4%), and Enterobacter cloacae (7.7%). The incidence of extended-spectrum beta-lactamase-producers was higher in Turkish, Russian and Italian ICUs (27.9-39.6%) than in other countries (2.5-10.8%). The frequency of AmpC-cephalosporin hyper-producers was 16.8-55.4%. Meropenem was more active against Proteus mirabilis than imipenem (99.0% versus 88.8% susceptibility, respectively). Against Acinetobacter baumannii, meropenem (79.6% susceptible) and imipenem (82.2%) were more active than comparators (34.3-51.6%). Meropenem and imipenem exhibited good activity against P. aeruginosa (76.1% and 68.2%, respectively; but with inter-country variation). Ciprofloxacin resistance in E. coli and K. pneumoniae increased and needs close monitoring. Meropenem (98.2-99.8% susceptibility) and imipenem (88.8-99.4%) remained potent against important species of gram-negative bacteria from European ICUs actively using meropenem.
机译:从参加美洛培南年度药敏试验信息收集(MYSTIC)计划(1997-2000)的29个欧洲ICU中收集了6243克阴性分离株的药敏数据。最常见的细菌是铜绿假单胞菌(22.5%),大肠杆菌(19.8%),肺炎克雷伯菌(10.4%)和阴沟肠杆菌(7.7%)。土耳其,俄罗斯和意大利的ICU(27.9-39.6%)的广谱β-内酰胺酶生产者发生率高于其他国家(2.5-10.8%)。 AmpC-头孢菌素高产者的发生率为16.8-55.4%。美罗培南对米氏变形杆菌的抵抗力比亚胺培南高(分别为99.0%和88.8%的敏感性)。针对鲍曼不动杆菌,美罗培南(易感的占79.6%)和亚胺培南(占82.2%)比对比例(34.3-51.6%)更有活性。美洛培南和亚胺培南对铜绿假单胞菌表现出良好的活性(分别为76.1%和68.2%;但国家间差异很大)。大肠杆菌和肺炎克雷伯菌的环丙沙星耐药性增加,需要密切监测。美洛培南(98.2-99.8%的药敏性)和亚胺培南(88.8-99.4%)仍然对使用美洛培南的欧洲重症监护病房的革兰氏阴性细菌的重要种类有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号